Prenetics Global (Prenetics Global) ROCE % : -21.84% (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Prenetics Global ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Prenetics Global's annualized ROCE % for the quarter that ended in Sep. 2023 was -21.84%.

Prenetics Global ROCE % Historical Data

The historical data trend for Prenetics Global's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prenetics Global ROCE % Chart

Prenetics Global Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-12.08

-279.74

-106.10

-24.08

Prenetics Global Quarterly Data
	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial									49.84	-17.50	-23.00	-21.84	-20.36

Prenetics Global ROCE % Calculation

Prenetics Global's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-182.861	/	( ( (148.507 - 58.738)	+	(312.131 - 57.195) )	/ 2 )
	=	-182.861	/	( (89.769	+	254.936)	/ 2 )
	=	-182.861	/	172.3525
	=	-106.10 %

Prenetics Global's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	-50.776	/	( ( (280.84 - 52.028)	+	(276.415 - 40.34) )	/ 2 )
	=	-50.776	/	( ( 228.812	+	236.075 )	/ 2 )
	=	-50.776	/	232.4435
	=	-21.84 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

Prenetics Global (NAS:PRE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Prenetics Global ROCE % Related Terms

Thank you for viewing the detailed overview of Prenetics Global's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Prenetics Global (Prenetics Global) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prenetics Global Ltd (NAS:PRE) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Unit 701-706, K11 Atelier King’s Road, 728 King’s Road, Quarry Bay, Hong Kong, HKG

Website

https://www.prenetics.com

Prenetics Global Ltd is a diagnostic and genetic testing company. It is a genomics and precision oncology company that has devised a method to integrate early detection for cancer, targeted therapy and direct-to-consumer genetic testing services into one comprehensive platform. It operates in two segments. The prevention segment includes the design & sale of genetics testing (including update services) & stool-based DNA tests for early colorectal cancer screening. The diagnostic segment includes the sale of COVID-19 testing services & products and precision oncology services. The majority of revenue is from the diagnostics segment. Geographically, it operates in Hong Kong and the United Kingdom, out of which the majority is from Hong Kong.